![3-Boc-3-azaspiro[5.5]undecane-9-carbaldehyde](https://file.medchemexpress.com/product_pic/hy-w056267.gif "Click to View 3-Boc-3-azaspiro[5.5]undecane-9-carbaldehyde Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
112 Results for "
SOS1
" in MedChemExpress (MCE) Product Catalog:
Products (112)
112 Results for "SOS1" in MCE Product Catalog:
Art. -Nr.: HY-148261
CAS. Nr.: 2749963-77-5
KRAS G12C inhibitor 56 (compound IC-6) is a potent SOS1 inhibitor with an IC50 of 1.6 nM. KRAS G12C inhibitor 56 can be used in cancer research [1].
Art. -Nr.: HY-161654
CAS. Nr.: 3043923-74-3
PROTAC SOS1 degrader-10 is a SOS1 PROTAC degrader dependent on CRBN and the proteasome. PROTAC SOS1 degrader-10 degrades SOS1 in KRAS-mutant cancer cells SW620, A549 and DLD-1, with DC50 values of 2.23, 1.85 and 7.53 nM, respectively. PROTAC SOS1 degrader-10 inhibits ERK phosphorylation. PROTAC SOS1 degrader-10 suppresses the proliferation of KRAS-mutant cancer cells via antiproliferative activity. PROTAC SOS1 degrader-10 can be used in studies related to KRAS-mutant cancers [1].
Art. -Nr.: HY-175560
CAS. Nr.: 3092445-74-1
SOS1-IN-22 is a son of sevenless homolog 1 (SOS1) inhibitor. SOS1-IN-22 can inhibit KRAS-G12C/SOS1 complex formation with an IC50 value of 40.28 nM. SOS1-IN-22 can reduce phosphorylation ERK levels. SOS1-IN-22 can be used for the research of cancer, such as pancreatic carcinoma and appendiceal carcinoma [1].
Art. -Nr.: HY-176170
SOS1-IN-19 (Compound 10i) is a potent inhibitor of SOS1 (Son of Sevenless 1) with an IC50 value of 165.2 nM. SOS1-IN-19 blocks KRAS activation by preventing GDP/GTP exchange in KRAS signaling pathway. SOS1-IN-19 is promising for research of KRAS-driven cancers (e.g., NSCLC and colorectal cancer) [1].
Art. -Nr.: HY-153674
PROTAC SOS1 degrader-4 (Compound 10) is a PROTAC degrader that targets the SOS1 protein for degradation by recruiting cereblon. It degrades SOS1 in NCI-H358, A-427, SW-620, and DLD-1 cells and inhibits the proliferation of various KRAS-mutant tumor cells, making it a useful tool for cancer research [1].
Art. -Nr.: HY-161233A
BTX-6654 formate is a SOS1 PROTAC degrader. BTX-6654 formate induces ubiquitination and degradation of SOS1 via the proteasomal pathway by bridging SOS1 with the E3 ligase CRBN to form a ternary complex, thereby blocking KRAS activation and downregulating the MAPK signaling pathway (pERK/pS6), and ultimately inhibiting tumor growth. BTX-6654 formate can be used in research on various cancers driven by KRAS mutations [1].
Art. -Nr.: HY-144657
CAS. Nr.: 2913176-81-3
Target:
Forschungsgebiete:
(4S)-PROTAC SOS1 degrader-1 is a stereoisomer of PROTAC SOS1 degrader-1 (HY-145737). PROTAC SOS1 degrader-1 (Compound 9d) is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 can be used for the research of KRAS-driven cancers [1].
Art. -Nr.: HY-161452
Forschungsgebiete:
SOS1 Ligand intermediate-3 (Compound 5) is an SOS1 binder that can be used together with pomalidomide (HY-10984) for the synthesis of SOS1 PROTACs [1].
Art. -Nr.: HY-W056267
CAS. Nr.: 1416176-14-1
Target:
Forschungsgebiete:
3-Boc-3-azaspiro[5.5]undecane-9-carbaldehyde is a PROTAC linker, and can be used for synthesis of PROTAC SOS1 degrader-8 (HY-161634) [1].
Art. -Nr.: HY-RS13576
Target:
Forschungsgebiete:
SOS1 Human Pre-designed siRNA Set A contains three designed siRNAs for SOS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-162281
CAS. Nr.: 3032282-51-9
PROTAC SOS1 degrader-6 is a selective SOS1 PROTAC degrader with a DC50 of 43-130 nM. PROTAC SOS1 degrader-6 induces ubiquitination and degradation of SOS1 via the ubiquitin-proteasome system by recruiting the E3 ligase VHL. PROTAC SOS1 degrader-6 reduces the levels of phosphorylated MEK and ERK. PROTAC SOS1 degrader-6 exerts antiproliferative effects in KRAS-driven cancer cells. PROTAC SOS1 degrader-6 can be used in research related to KRAS G12C-mutant cancers and chronic myeloid leukemia [1].
Art. -Nr.: HY-161173
CAS. Nr.: 2836273-61-9
PROTAC SOS1 degrader-5 is a potent SOS1 PROTAC degrader with a DC50 value of 13 nM. PROTAC SOS1 degrader-5 induces CRBN-dependent ubiquitination and degradation of SOS1 protein, inhibits the proliferation of KRAS G12C-mutated cancer cells, and suppresses tumor growth in xenograft models. PROTAC SOS1 degrader-5 can be used in studies related to KRAS G12C-mutated non-small cell lung cancer [1].
Art. -Nr.: HY-161655
CAS. Nr.: 3043923-70-9
Forschungsgebiete:
SOS1 Ligand intermediate-5 is the ligand for son of sevenless 1 (SOS1). SOS1 Ligand intermediate-5 is utilized for synthesis of PROTAC SOS1 degrader-10 (HY-161654) [1].
Art. -Nr.: HY-161635
CAS. Nr.: 3036155-94-6
Forschungsgebiete:
SOS1 Ligand intermediate-4 is a ligand of SOS1, used for the synthesis of PROTAC SOS1 degrader (HY-161634) [1].
Art. -Nr.: HY-169371
CAS. Nr.: 2836274-66-7
Target:
Forschungsgebiete:
SOS1 Ligand intermediate-7 (65) is an intermediate for the synthesis of SOS1 ligand (HY-111671). SOS1 activator 1 (HY-111671) can be used for the synthesis of PROTAC SOS1 degrader-1 (HY-145737) [1].
Art. -Nr.: HY-P2265
CAS. Nr.: 1652561-87-9
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
